加州猴痘疫苗接种系列完成情况的人口学差异:按疫苗给药途径分析,2022年8月9日至2023年3月31日
加州公共卫生部调查2022年8月9日至2023年3月31日期间接种首剂JYNNEOS疫苗的加州居民,分析接种系列完成率是否因首剂给药途径而异。总体完成率为59.8%,非西班牙裔白人、≥65岁及出生时指定男性性别者完成率较高,非西班牙裔黑人或非裔美国人、18-24岁及出生时指定女性性别者较低。首剂皮下接种时完成率为58.8%,皮内接种时为60.2%;在各race和ethnicity组、18-64岁人群、社区健康状况及出生时指定男性性别者中,首剂皮下接种的完成 odds 不高于皮内接种。JYNNEOS疫苗皮内使用未降低总体两剂系列完成率。
要点
- 加州2022年8月9日至2023年3月31日首剂接种者中,59.8%完成了第二剂。
- 完成率最高为非西班牙裔白人(64.1%)、≥65岁(72.6%)及出生时指定男性性别者(62.1%)。
- 完成率最低为非西班牙裔黑人或非裔美国人(51.3%)、18-24岁(42.9%)及出生时指定女性性别者(42.8%)。
核心结论
- JYNNEOS疫苗皮内使用未降低总体两剂系列完成率。
- 需要持续努力确保猴痘病毒感染风险人群接种两剂推荐剂量。
研究设计与样本
- 加州公共卫生部调查2022年8月9日至2023年3月31日期间接种首剂JYNNEOS疫苗的加州居民,分析接种系列完成率是否因首剂给药途径而异。
主要发现
- 首剂接种者中总体第二剂完成率为59.8%。
- 完成率最高为非西班牙裔白人(64.1%)、≥65岁者(72.6%)及出生时指定男性性别成人(62.1%)。
- 完成率最低为非西班牙裔黑人或非裔美国人(51.3%)、18-24岁者(42.9%)及出生时指定女性性别成人(42.8%)。
- 首剂皮下接种时总体系列完成率为58.8%,首剂皮内接种时为60.2%。
- 在所有race和ethnicity组、18-64岁者、社区健康状况及出生时指定男性性别者中,首剂皮下接种的系列完成 odds 不高于皮内接种。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In August 2022, the Food and Drug Administration authorized JYNNEOS vaccine (modified vaccinia Ankara vaccine, Bavarian Nordic), a 2-dose series used for the prevention of Monkeypox virus infection, to be administered via a dose-sparing intradermal route, in addition to the previously authorized subcutaneous route. The California Department of Public Health investigated whether demographic disparities in vaccination series completion varied by route of administration of the recipient's first dose. Among California residents who received their first dose during August 9, 2022-March 31, 2023, a total of 59.8% received a second dose. Series completion was highest among non-Hispanic White persons (64.1%), persons aged ≥65 years (72.6%), and adults with male sex assignment at birth (62.1%); series completion was lowest among non-Hispanic Black or African American persons (51.3%), persons aged 18-24 years (42.9%), and adults assigned female sex at birth (42.8%). When the first dose was received by subcutaneous administration, overall series completion was 58.8% compared with 60.2% when the first dose was administered intradermally. Odds of series completion across all race and ethnicity groups, persons aged 18-64 years, community health conditions, and persons assigned male sex at birth were not greater when the first dose was administered subcutaneously compared with intradermally. Intradermal use of JYNNEOS vaccine did not lower overall 2-dose series completion rates. Continued efforts are needed to ensure persons at risk for Monkeypox virus infection receive both recommended doses.
引用
- Salih T, Vance J, Quint J, et al. Demographic Disparities in Mpox Vaccination Series Completion, by Route of Vaccine Administration - California, August 9, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37498796. doi:10.15585/mmwr.mm7230a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。